PTPN11

Overview

PTPN11 encodes SHP2 (Src homology-2-containing protein tyrosine phosphatase 2), a non-receptor protein tyrosine phosphatase that plays a central role in intracellular signal transduction. SHP2 is widely recognized as a key regulator of signaling downstream of growth factor receptors and other upstream inputs, where it helps modulate pathways such as MAPK/ERK/JNK signaling pathways and PI3K/AKT/mTOR pathway. Through these functions, PTPN11 influences cell proliferation, differentiation, survival, and broader oncogenic signaling networks.

Clinically and biologically, PTPN11 is important because altered SHP2 activity is implicated in cancer and developmental disorders. In the recent literature provided here, PTPN11 is discussed both as a mechanistic driver of signaling and as a therapeutic target, particularly in the context of allosteric SHP2 inhibition. The gene is also noted as a major disease gene in Noonan syndrome, where pathogenic variants disrupt normal SHP2 function.

Recent Publications Focus

Below is a summary of the newest research publications targeting PTPN11 (sorted by publication date).

Recent studies have focused heavily on SHP2 inhibition in cancer, especially in Kras-driven and receptor tyrosine kinase–associated settings. A 2026 Journal of medicinal chemistry study reported the development of furanyl amide-based SHP2 allosteric inhibitors through optimization of the in-house lead compound SDUY038, with the goal of improving therapeutic potential against Kras-driven pancreatic cancer. In the same disease context, another 2026 study described SHP2 inhibition as revealing compensatory PI3K-AKT activation in Kras-driven pancreatic cancer and introduced SDUY104, emphasizing the need for rational combination therapy to overcome adaptive signaling responses. These findings reinforce the role of PTPN11 as a signaling node whose inhibition can trigger pathway rewiring, particularly involving PI3K/AKT signaling.

Structural and mechanistic work has also examined how SHP2 regulation affects inhibitor response. A 2026 Journal of biomolecular structure & dynamics paper investigated the allosteric effect of SHP2 Tyr62 phosphorylation on acquired resistance to the allosteric inhibitor SHP099, identifying phosphorylation as a factor influencing inhibitor sensitivity. This study framed SHP2 as a dynamic regulatory protein whose conformational state can affect drug response. In parallel, a 2026 Journal of medicinal chemistry report described dual allosteric targeting of SHP2 through the development of bivalent inhibitors with enhanced potency for cancer treatment, highlighting a strategy to improve SHP2-directed pharmacology beyond single-site inhibition. Together, these studies underscore ongoing efforts to refine SHP2-targeted drug design.

Combination therapy studies further support PTPN11 as a partner target in pathway-based cancer treatment. A 2026 Lung Cancer paper evaluated lorlatinib combined with MAPK pathway inhibitors, including binimetinib and TNO155, in previously treated ALK- or ROS1-rearranged lung cancer. In this setting, TNO155 served as an SHP2 inhibitor used alongside ALK/ROS1-targeted therapy, reflecting the rationale that SHP2 blockade may help suppress adaptive MAPK signaling. Related to this theme, the publication context also mentions MAPK pathway inhibition and the broader use of SHP2 inhibition in combination regimens, although no clinical approval has yet been reported for such combinations in the cited work.

Several studies used biochemical, cellular, and computational methods to characterize SHP2-target interactions and downstream effects. The methods included AlphaScreen-based assays, Western blotting analysis, colony formation and flow cytometry assays, phosphoproteomics, dynamic light scattering, transmission electron microscope, SpyTag/SpyCatcher system, molecular dynamics simulations, multiple replica molecular dynamics simulations, and binding free energy calculations. These approaches were used to assess inhibitor binding, conformational behavior, nanoparticle assembly, and signaling consequences. For example, phosphoproteomics was used in a 2026 study examining the functional impact of the PTPN11 p.Asn308Ser variant in a Noonan syndrome pedigree, supporting the statement that mutations in PTPN11 encoding SHP2 are the most prevalent genetic cause of Noonan syndrome. This work linked a specific variant to altered phosphorylation-related signaling behavior.

PTPN11 also appeared in broader target-discovery and docking-based cancer research. A 2026 Chemico-biological interactions study on di-(2-ethylhexyl) terephthalate (DOTP) used molecular docking to identify several high-affinity carcinogenic targets, including PTPN11, PIK3CA, ESR1, PPARG, PTGS2, and MAPK1. Although this was not a direct SHP2-targeted therapeutic study, it placed PTPN11 among candidate proteins implicated in chemical carcinogenicity and signaling disruption.

Finally, one 2026 Antiviral Research publication mentioned PTPN11 only in the broader context of nanoparticle vaccine engineering, where self-assembled EDIII/NS1 nanoparticle vaccines were created by covalently conjugating protein subunits to the mi3 scaffold using the SpyTag/SpyCatcher system. This study was not a PTPN11-directed therapeutic investigation, but it illustrates the range of experimental platforms appearing in the recent literature set. Overall, the newest publications portray PTPN11/SHP2 as a highly active target in precision oncology and signaling biology, with ongoing work focused on allosteric inhibition, resistance mechanisms, and combination strategies involving Kras, PI3K/AKT, MAPK/ERK/JNK, and ALK/ROS1-related pathways.

Background PMIDs

• [PMID 42133826]
• [PMID 41671625]

Target PMIDs

• [PMID 42105811]
• [PMID 42261691]
• [PMID 40432314]
• [PMID 42133826]
• [PMID 41780785]
• [PMID 41843963]